Sana Biotechnology, Inc.

Listed Company

SANACIK 0001770121NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-244.17M

Total Assets

$416.89M

Equity

$160.88M

Shares Out

278.29M

Op. Cash Flow

$-143.83M

SANA$3.13−29.66% · past yearDBEQ Basic

Daily closing prices

Business

Sana Biotechnology develops engineered cell therapies using proprietary ex vivo and in vivo cell engineering platforms. The ex vivo platform creates hypoimmune allogeneic cells for diseases including type 1 diabetes and B cell cancers; SC451, a stem cell-derived pancreatic islet therapy, is its lead program. The in vivo platform uses fusogen-based delivery to engineer T cells in the body; SG293, a CAR T therapy for B cell malignancies, is its advanced program. Sana operates globally with worldwide rights to its candidates.

Summary from 10-K filed 2026-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	132	216	262	286	249
Research and development related success payments and contingent consideration	29	−9	−49	−85	58
General and administrative	44	64	73	72	50
Impairment of long-lived assets	45	2	7	—	—
Total operating expenses	250	273	293	273	357
Loss from operations	−250	−273	−293	−273	−357
Interest income, net	4	10	10	4	676,000
Other income (expense), net	2	−5	−52,000	−674,000	305,000
Net loss	−244	−267	−283	−269	−356
Net loss per common share - basic	−0.96	−1.16	−1.46	−1.43	−2.14
Net loss per common share - diluted	−0.96	−1.16	−1.46	−1.43	−2.14
Weighted-average number of common shares - basic	253	231	195	188	166
Weighted-average number of common shares - diluted	253	231	195	188	166

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	72	128	134	177	253
Marketable securities	67	25	72	247	298
Restricted cash	4	4	4	6	—
Prepaid expenses and other current assets	6	4	4	14	7
Total current assets	149	161	214	444	558
Property and equipment, net	27	77	71	67	65
Operating lease right-of-use assets	38	58	75	92	96
Intangible asset	59	59	59	59	59
Goodwill	141	141	141	141	141
Other non-current assets	3	5	6	5	5
TOTAL ASSETS	417	501	565	823	1,129
Accounts payable	2	5	4	3	2
Accrued compensation	13	14	24	26	21
Accrued expenses and other current liabilities	9	13	23	15	10
Operating lease liabilities	15	13	13	12	9
Contingent consideration	40	0	—	55	51
Total current liabilities	79	45	64	112	99
Operating lease liabilities, net of current portion	64	82	91	96	102
Contingent consideration, net of current portion	84	109	110	95	102
Success payment liabilities	19	5	13	21	98
Other non-current liabilities	11	10	—	—	—
Total liabilities	256	251	278	323	401
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	—	—	—	—
Common stock, $0.0001 par value; 750,000 shares authorized; 266,732 and 223,923 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	27,000	22,000	20,000	19,000	18,000
Additional paid-in capital	2,010	1,855	1,626	1,558	1,515
Accumulated other comprehensive income	28,000	14,000	−60,000	−4	−1
Accumulated deficit	−1,800	−1,605	−1,338	−1,055	−785
Total stockholders' equity	161	251	288	499	729
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	417	501	565	823	1,129

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−244	−267	−283	−269	−356
Depreciation	13	16	18	16	11
Stock-based compensation expense	25	38	36	38	22
Change in the estimated fair value of contingent consideration	15	−638,000	−41	−3	32
Change in the estimated fair value of success payment liabilities	15	−8	−8	−82	26
Non-cash expense for operating lease right-of-use assets	9	10	13	12	7
Impairment of long-lived assets	45	2	7	—	—
Other non-cash items, net	−11	−11	−13	−9	−3
Prepaid expenses and other assets	1	−4	8	−6	−861,000
Operating lease right-of-use assets and liabilities	−3	9	11	2	5
Accounts payable	−4	1	1	1	−266,000
Accrued expenses and other liabilities	−5	−8	−2	11	6
Net cash used in operating activities	−144	−223	−254	−290	−251
Purchases of marketable securities	−87	−226	−158	−79	−491
Proceeds from maturities of marketable securities	47	277	350	310	280
Purchases of property and equipment	−938,000	−33	−20	−21	−30
Proceeds from disposal of assets	1	0	0	—	—
Net cash provided by (used in) investing activities	−40	17	172	211	−246
Proceeds from employee stock purchase plan and exercise of stock options	3	11	5	4	—
Proceeds related to common stock financings, net	126	181	27	4	5
Proceeds (principal payments), net for tenant improvement loan	−347,000	8	0	—	—
Net cash provided by financing activities	129	200	32	5	632
Net decrease in cash, cash equivalents, and restricted cash	−55	−6	−50	−75	135
Operating lease right-of-use assets obtained in exchange for lease obligations	0	0	9	21	40
Purchases of property and equipment included in accounts payable and accrued liabilities	0	0	9	1	3
Cash received for tenant improvement allowances	891,000	8	13	2	5
Derecognition of operating lease right-of-use assets for lease termination and modification	−3	−7	−14	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Sana Biotechnology, Inc.'s CIK number?

Sana Biotechnology, Inc.'s SEC CIK number is 0001770121 (1770121). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Sana Biotechnology, Inc.'s SEC filings?

All of Sana Biotechnology, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Sana Biotechnology, Inc. last report earnings?

Sana Biotechnology, Inc. (SANA) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-216758). This is Sana Biotechnology, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Sana Biotechnology, Inc.'s most recent earnings 8-K?

Sana Biotechnology, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-216758. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Sana Biotechnology, Inc.'s latest earnings 8-K →
Look up any company's CIK number →